cGxP.wire https://validator.w3.org/feed/docs/rss2.html Neurosterix Completes Phase 1 Studies of NTX-253 Lantern Pharma Advances LP-300 Phase 2 Trial in Taiwan Rocket Pharmaceuticals Advances RP-A501 Danon Disease Trial IQVIA Launches Explorer to Accelerate Commercial Decisions Ribo Files EU Clinical Trial Application for Obesity Drug RBD3133 Pearl Diagnostics Reports Clinical Evidence for MycoMEIA Assay Pfizer Wins FDA Approval for TUKYSA in Front-Line Breast Cancer Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial Glaukos Reports Three-Year Epioxa Results in Keratoconus argenx Reports Positive Phase 2 Results for FB102 in Celiac Disease IQVIA Launches AI Models to Predict Clinical Trial Outcomes Galderma Reports Three-Year Nemluvio Data in Atopic Dermatitis Bayer FDA Accepts Finerenone Application for CKD Without Diabetes argenx Discontinues Phase 3 UNITY Study in Sjögren’s Disease Theialife Aligns with FDA on ND10 Phase 3 Myopia Program Victory Square Announces U.S. Patent Allowance for Insu Atsena Reports Positive ATSN-201 Data in XLRS Trial Saol Therapeutics Completes Phase III Knee Pain Trial Enrollment PreludeDx Reports Independent Validation of AidaBREAST Test Nuevocor Doses First Patient in NVC-001 Heart Disease Trial Boehringer Ingelheim Launches Quarterable PREVICOX Tablets BioLineRx and Hemispherian Present GLIX1 Brain Cancer Data MRI2CT Wins FDA Clearance for AI-Powered NextMR Platform Biohaven Signs $100M Ono Deal for IgG Degrader Drugs Dignify Therapeutics Wins FDA IND Clearance for DTI-117 Draper Wins $7.3M ARPA-H Award for Room-Temp Biologics Resolve Therapeutics Completes Phase 2 Sjögren’s Trial Enrollment AusperBio to Present Long-Term AHB-137 Hepatitis B Data Asieris Licenses CEVIRA® to Theramex in $250M Deal AmyriAD Acquires Recognify to Expand Cognition Pipeline FibroBiologics Files Patent for Cell-Based GLP-1 Production AbbVie Wins Two FDA Breakthrough Designations for Temab-A Kyverna to Present Miv-cel Data in SPS and Multiple Sclerosis Immunic Advances Vidofludimus Calcium MS Data at MSToronto2026 MimiVax Reports SurVaxM Phase 2b Glioblastoma Data Mentara Therapeutics Advances MTA-304 for Parkinson’s Byondis Advances ADC Platforms and BYON14156 Toward Clinic MAIA Advances Ateganosine NSCLC Trial Enrollment Milestones SeaStar Medical Wins FDA Breakthrough Device Designation SciSparc Reports Quantum-Enabled Gene Analysis Acceleration Propanc Reports 90% Tumor Growth Inhibition with PRP RenovoRx Enrolls First Patient in PRISM-TAMP Trial Clearmind Submits FDA Recommendations on Neuroplastogen Therapies Artelo Biosciences to Present FABP5 Program at BIO-Europe BioCardia Advances CardiAMP HF II Trial Toward FDA Approval AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Strategy Novartis Wins FDA Approval for Rhapsido in Dermographism Zealand Pharma Reports Positive Phase 2 Petrelintide Data vTv Therapeutics Wins FDA Orphan Drug Designation for HPPD Pulse Biosciences Completes NANOPULSE-AF Enrollment